Efficacy of lamivudine and adefovir de novo combination therapy or after mono-th

StephenW

Zhonghua Gan Zang Bing Za Zhi. 2012 Feb;20(2):98-102. doi: 10.3760/cma.j.issn.1007-3418.2012.02.006.
Efficacy of lamivudine and adefovir de novo combination therapy or after mono-therapy in chronic hepatitis B patients. [Article in Chinese]
Ma XJ, Chen XP, Chen XF, Chen WL, Huang J, Chen R, Luo XD, Ma HY.
SourceDepartment of Infectious Disease, Guangdong General Hospital, Guangdong Academy of Medical Sciences; Guangzhou, Guangzhou 510300, China.

AbstractTo investigate the efficacy of 104 weeks of lamivudine (LAM) and adefovir (ADV) de novo combination therapy, as compared to optimized combination therapy administered after 48 weeks of treatment with lamivudine or adefovir mono-therapy, in chronic hepatitis B (CHB) patients. A total of 174 patients with CHB were equally divided among three treatment groups: LAM mono-therapy; ADV mono-therapy; and LAM + ADV combination therapy. The patients in the LAM + ADV group were treated with LAM plus ADV for 104 consecutive weeks. The patients in the LAM or the ADV groups were first treated for 48 weeks with LAM or ADV, respectively, after which the patient's virological response was assessed. Accoring to the results, the patient was continued on mono-therapy or switched to combination therapy for the subsequent 56 weeks. Virological and biochemical examinations were carried out at weeks 48 and 104. The rates of undetectable HBV DNA in the LAM mono-therapy, ADV mono-therapy, and LAM-ADV combination therapy groups at week 48 were 68%, 50%, and 84%, and at week 104 were 80%, 72%, and 95%, respectively. For the same groups, the virus breakthrough rates at week 48 were 15%, 0%, and 0%, and at week 104 were 18%, 2%, and 0%, respectively. Statistical analysis showed significant differences for the rate of undetectable HBV DNA between LAM + ADV group and LAM group at week48 (x2 = 4.473, P= 0.034) and at week 104 (x2 = 5.795, P = 0.016), LAM + ADV group and ADM group at week48 (x2 = 14.802, P less than 0.001) and week 104 (x2 = 5.547, P = 0.001). The hepatitis B e antigen (HBeAg) seroconversion rates at week 48 were 15% (x2 = 4.543, P = 0.033), 13% (x2 = 4.035, P = 0.045) and 38%, and at week 104 were 21% (x2 = 4.438, P = 0.035), 17% (x2 = 4.223, P = 0.04) and 44%, respectively, among patients positive for HBeAg. Statistical analysis showed that the differences among the three groups for each of these parameters were statistically significant (all, P less than 0.05). When compared with LAM or ADV mono-therapy followed by LAM+ADV at week 48, the LAM plus ADV de novo combination therapy for 104 weeks provided CHB patients with better virological and serological responses and a lower drug resistance rate.

StephenW

中华肝脏病杂志。 2012 02 20（2）:98-102。 DOI：10.3760/cma.j.issn.1007-3418.2012.02.006。
[拉米夫定和阿德福韦从头联合治疗后的疗效单一治疗慢性乙型肝炎乙型肝炎患者。
[文章在中国]
陈轮候册，马杰，陈XP，陈兴芳，黄建，陈荣，罗XD，马兴业。
源
传染病部，广东省人民医院，广东省医学科学院，广州，广州510300，中国。

摘要

为了探讨拉米夫定（LAM）和阿德福韦（ADV），从头联合治疗104周相比，优化组合疗法治疗慢性乙型肝炎（CHB）患者使用拉米夫定或阿德福韦单一治疗，48周后，管理的有效性。共有174例慢性乙型肝炎患者均分三组：林单疗法; ADV单治疗;林+动词组合治疗。在林+ ADV组患者均连续104周林加ADV。在LAM或ADV组患者首次与林或ADV治疗48周，分别评估后，患者的病毒学应答。病人Accoring的结果，是继续治疗单或随后的56周的联合疗法。病毒学和生化检查进行了48周和104周。林单治疗，ADV单一疗法，结合的LAM-ADV治疗组48周不到HBV DNA的比例分别为68％，50％和84％，104周时分别为80％，72％，和95％，分别。对于同一组，在48周的病毒的突破率分别为15％，0％和0％，104周时分别为18％，2％和0％，分别。统计分析表明，在week48率不到HBV DNA的林+ ADV组和LAM组之间差异显着（χ2= 4.473，P = 0.034）和104周（X2 = 5.795，P = 0.016），林+ ADV组和在week48 ADM组（X2 = 14.802，P小于0.001）和104周（X2 = 5.547，P = 0.001）。 （X2 = 4.543，P = 0.033），乙肝e抗原（HBeAg）血清转换率在48周分别为15％，13％（X2 = 4.035，P = 0.045）和38％，并在104周的21％（X2 = 4.438，P = 0.035），17％（X2 = 4.223，P = 0.04）和44％，HBeAg阳性的患者中，。统计分析表明，这些参数的三组间差异有统计学意义（所有，磷小于0.05）。林或ADV单一治疗48周林+动词相比，104周林加上ADV的重新组合治疗慢性乙型肝炎患者提供更好的病毒学和血清学反应和耐药率较低。

咬牙硬挺

科技与进化的比赛

sunpk861007

有这么大的E血清转换率吗

StephenW

回复 sunpk861007 的帖子

Hepatology - Management of Hepatitis B Infection
        Authors: Harry L. A. Janssen, MD, PhD, Milan J. Sonneveld, MSc
HBeAg seroconversion rate after 1 year:1年后HBeAg的血清转换率

Lamivudine 18%
Adefovir 12%

从论文的数字相似.